The Trump administration announced a significant policy shift that will impose a 100% tariff on branded pharmaceuticals imported into the United States unless manufacturers agree to government pricing deals or commit to domestic production. This initiative aims to pressure drugmakers to localize manufacturing and reduce prescription drug prices for American consumers. Large pharmaceutical companies have 120 days to announce plans to avoid the tariff, while smaller companies have 180 days. By relocating production to the U.S., companies can benefit from a reduced 20% tariff. The administration has already reached agreements with 17 drugmakers, with 13 finalized and four under negotiation. Drugs produced in countries like the European Union, Japan, South Korea, and Switzerland will face a lower 15% tariff due to existing trade agreements. This move comes as U.S. patients pay significantly higher prices for prescription medications compared to other developed nations. The administration's push for lower prices is part of a broader strategy to align U.S. drug costs with those in high-income countries.